Basic research studies have shown for example that miRNA-768-3p drives K-RAS expression and is associated with resistance to anti-tumor treatment in BM; results of therapy with a miRNA-768-3p inhibitor in vitro reveal decreased miRNA-768-3p in patient BM compared to normal brain tissue and primary tumor tissue from the same patient (1). Here, KRAS is linked to neoplasm.